This article is rated C-class on Wikipedia's
content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Ideal sources for Wikipedia's health content are defined in the guideline
Wikipedia:Identifying reliable sources (medicine) and are typically
review articles. Here are links to possibly useful sources of information about Ensitrelvir.
|
It is requested that a photograph be
included in this article to
improve its quality.
Wikipedians in Japan may be able to help! The external tool WordPress Openverse may be able to locate suitable images on Flickr and other web sites. |
It is requested that a logo be
included in this article to
improve its quality. For more information, refer to discussion on this page and/or the listing at Wikipedia:Requested images. The Free Image Search Tool may be able to locate suitable images on Flickr and other web sites. |
https://asia.nikkei.com/Spotlight/Coronavirus/Shionogi-in-talks-with-U.S.-to-supply-COVID-oral-drug 2600:1700:8660:E180:35:9F96:F2C6:2D0F ( talk) 05:56, 25 April 2022 (UTC)
https://www.shionogi.com/global/en/news/2022/11/e20221122.html
https://www.bloomberg.com/news/articles/2022-11-22/shionogi-s-covid-pill-xocova-wins-japanese-panel-backing 97.35.0.38 ( talk) 15:10, 26 November 2022 (UTC)
https://asia.nikkei.com/Business/Pharmaceuticals/Drugmaker-Shionogi-inks-deal-to-market-COVID-pill-in-China 172.87.166.242 ( talk) 16:48, 30 December 2022 (UTC)
https://www.shionogi.com/global/en/news.html
Jun.26, 2023 Seven manufacturers sign sublicence agreements with the Medicines Patent Pool to produce generic versions of #Shionogi's COVID-19 oral antiviral ensitrelvir to increase access in low- and middle-income countries.
https://www.shionogi.com/global/en/news/2023/6/20230626-2.html
2023/06/26
Under the terms of the licence agreement, the seven selected generic manufacturers will be able to manufacture and supply ensitrelvir in 117 low- and middle-income countries (LMICs), pending regulatory authorisation or approval in those countries.
At least these countries are mentioned: Ukraine, China, South Africa.
Apr.11, 2023 Shionogi filed for Emergency Use Authorization of Ensitrelvir Fumaric Acid in Taiwan, for the Treatment of COVID-19
Apr.04, 2023 Shionogi Receives U.S. FDA Fast Track Designation for Ensitrelvir Fumaric Acid, an Investigational Oral Antiviral for COVID-19
Jan.04, 2023 New Drug Application of Ensitrelvir Fumaric Acid, a Therapeutic Drug for COVID-19 Accepted for Review in South Korea
91.159.186.9 ( talk) 17:14, 29 July 2023 (UTC)
https://asia.nikkei.com/Spotlight/Coronavirus/Japan-s-Shionogi-seeks-approval-for-COVID-pill-in-South-Korea 2600:8804:6600:45:78FF:CBD5:85A4:C357 ( talk) 01:30, 5 January 2023 (UTC)
Ensitrelvir (Xocova) and Nirmatrelvir (Paxlovid) are both sars2 main protease inhibitors
It should be mentioned that they have the same mechanism of action.
It is good Paxlovid has a competitor.
/info/en/?search=Nirmatrelvir/ritonavir
Other covid-19 drugs have different mechanisms, for example Molnupiravir.
91.159.186.9 ( talk) 17:05, 29 July 2023 (UTC)